ALFA FinderBSE filing, NSE: SAHLIBHFI. Summary written from the filing by ALFA Finder's alert engine.
Shalibhadra Finance Ltd: key numbers
- Share price
- ₹72.23
- Market cap
- ₹223.1 Cr
- Revenue (annual)
- ₹41.05 Cr
- Net profit (annual)
- ₹19.48 Cr
- P/E (TTM)
- 11.2×Sector 20.5×
- Promoter holding
- 58.10%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalibhadra Finance Ltd
All →Shalibhadra Finance Other Announcement
Shalibhadra Finance Ltd filed its quarterly shareholding pattern as of 30 September 2026. The promoter and promoter group hold about 58.10% of 30,88,84,00 shares.
Shalibhadra Finance Board Meeting Date
Shalibhadra Finance will hold a board meeting on 14 November 2026 to consider unaudited quarterly and half-year results for September 2026. The trading window stays closed till results.
Shalibhadra Finance Debt & Borrowing: ₹0.19 Cr
Shalibhadra Finance paid Rs.0.19 Crore monthly interest on its 11.5% NCDs, due October 29, 2026. Routine servicing of an existing debt obligation.
- Value
- ₹0.19 Cr
Shalibhadra Finance Other Announcement
Shalibhadra Finance Limited has filed its quarterly shareholding pattern under Regulation 31. This routine disclosure details the company's equity ownership structure for the period.
Shalibhadra Finance Management Change
Shalibhadra Finance submitted the resignation letter of its Company Secretary, Megha Singh, which was omitted from the initial announcement. The departure was effective October 1, 2026.
Shalibhadra Finance Debt & Borrowing: ₹24 Cr
Shalibhadra Finance Limited's board approved issuing secured non-convertible debentures worth up to ₹24 Crore on a private placement basis.
- Value
- ₹24.00 Cr
Other product launch announcements
All →Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.
JBM Auto Product Launch
JBM Electric Vehicles launched the all-electric ECOLIFE e12 city bus at Singapore Urban Mobility Week 2026. It cites 20,000-bus annual capacity and a new Singapore APAC hub.
- electric bus manufacturing capacity
- 20000.0 buses per annum
Restaurant Brands Asia Product Launch
Burger King India launches a limited-edition Avengers: Doomsday Collection across nationwide restaurants. The menu features themed burgers, sides, and merchandise starting at ₹199.